Related Experiment Video
Updated: Sep 12, 2025
07:46
CRISPR/Cas9 Editing of the C. elegans rbm-3.2 Gene using the dpy-10 Co-CRISPR Screening Marker and Assembled Ribonucleoprotein Complexes.
Published on: December 11, 2020
6.0K
CRISPR RiPCA for Investigating eIF4E-m7GpppX Capped mRNA Interactions.
Gabriela Vega-Hernández1, Jesse Duque2, Brandon J C Klein3
1Program in Chemical Biology, University of Michigan, Ann Arbor, Michigan 48109, United States.
ACS Chemical Biology
|August 7, 2025
Summary
Researchers developed CRISPR RiPCA, a new platform for studying RNA-protein interactions in live cells. This tool measures the activity of cancer drug inhibitors targeting eukaryotic translation initiation factor 4E (eIF4E) interactions.
Area of Science:
- Molecular Biology
- Biochemistry
- Genomics
Background:
- Post-transcriptional modifications of mRNA are regulated by reader RNA-binding proteins (RBPs).
- Dysregulation of RBPs is linked to diseases like cancer, neurodegeneration, and viral infections.
- Targeting RBPs offers a therapeutic strategy for restoring cellular function.
Purpose of the Study:
- To develop a novel platform for live-cell measurement of RNA-protein interactions (RPIs).
- To validate the platform using the interaction between eukaryotic translation initiation factor 4E (eIF4E) and its RNA substrate.
- To demonstrate the platform's utility in assessing drug candidate efficacy.
Main Methods:
- Coupling CRISPR technology with the RNA interaction with Protein-mediated Complementation Assay (RiPCA).
- Establishing a live-cell RPI assay named CRISPR RiPCA.
- Utilizing the eIF4E and m7G-capped RNA interaction as a model system.
Main Results:
- Demonstrated the successful development of the CRISPR RiPCA platform.
- Showcased the ability of CRISPR RiPCA to measure on-target activity of eIF4E inhibitors.
- Validated the platform's potential for cancer drug discovery.
Conclusions:
- CRISPR RiPCA is a powerful new tool for studying RPIs in live cells.
- The platform enables the assessment of therapeutic interventions targeting RBPs.
- This technology holds promise for advancing drug discovery in oncology and other RBP-dysregulated diseases.
Related Concept Videos
01:28CRISPR/Cas9 Genome Editing
227
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
227
02:53CRISPR and crRNAs
17.4K
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
17.4K